Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | NCF1 | P14598 | 2/20 | 0.36 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.36 |
| ▸ | HTR3B | O95264 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | HTR1D | P28221 | 1/20 | 0.36 |
| ▸ | HTR1B | P28222 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21733903 | 0.84 | KRAS (0.45) | HTR2CCYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL30834581 | 0.84 | KRAS (0.45) | HTR2CCYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL21733719 | 0.82 | KRAS (0.53) | — | |
| SCHEMBL30177853 | 0.82 | KRAS (0.53) | — | |
| SCHEMBL30177996 | 0.82 | KRAS (0.53) | — | |
| SCHEMBL21733709 | 0.82 | KRAS (0.53) | — | |
| SCHEMBL21722179 | 0.82 | KRAS (0.53) | — | |
| SCHEMBL30834556 | 0.82 | CYP1A2 (0.41) | HTR2CCYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL21722152 | 0.82 | CYP1A2 (0.41) | HTR2CCYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL21259505 | 0.80 | HRH4 (0.42) | HTR2CCYP1A2CYP3A4CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112119075-B | Condensed ring compound | 豪夫迈·罗氏有限公司 | 2024-03-12 | — | — | CN | disclosed |
| US-11760744-B2 | Fused ring compounds | GENENTECH, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20230002345-A1 | FUSED RING COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-01-05 | — | — | US | disclosed |
| CN-112119075-A | Fused ring compound | 豪夫迈·罗氏有限公司 | 2020-12-22 | — | — | CN | disclosed |
| EP-3746436-A1 | FUSED RING COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2020-12-09 | — | — | EP | disclosed |
| WO-2020035031-A1 | FUSED RING COMPOUNDS | GENENTECH, INC. (US) | 2020-02-20 | — | — | WO | disclosed |
| WO-2020035031-A1 | FUSED RING COMPOUNDS | GENENTECH, INC. (US) | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11760744-B2 | Fused ring compounds | KRAS, NRAS, HRAS | HTR2C 4653/4885LRRK2 295/4885CYP1A2 3503/4885 |
| US-20230002345-A1 | FUSED RING COMPOUNDS | KRAS, NRAS, HRAS | HTR2C 4653/4885LRRK2 295/4885CYP1A2 3503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.